Please wait a minute...
European Journal of Gynaecological Oncology  2021, Vol. 42 Issue (4): 634-642    DOI: 10.31083/j.ejgo4204098
Special Issue: Update on Cervical Cancer Prevention and Screening
Original Research Previous articles | Next articles
Developing evidence-based Multisociety Italian Guidelines for cervical cancer prevention: rationale, methods, and development process
Francesco Venturelli1, *, †() on behalf of the Multisociety Italian Guidelines for cervical cancer prevention Working Group
1Multisociety Italian Guidelines for Cervical Cancer Prevention Working Group, Italy
Download:  PDF(292KB)  ( 90 ) Full text   ( 19 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: Cervical cancer prevention shows a variability across Italian Regions unjustified by available evidence, increasing the health, economic and organizational burden. Evidence-based recommendations on topics not covered by international guidelines are needed to tackle existing inequalities. This article describes the rationale, methods, and process for development of the Multisociety Italian Guidelines for cervical cancer prevention. Methods: The Italian legislative framework requires guidelines to be consistent with methodological standards set by the National System for Guidelines (SNLG) of the National Institute of Health. Results: The nine scientific societies involved in cervical cancer prevention participated to the project, including clinicians, policy makers, methodologists, and researchers. Patients were involved as full voting panel members. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach was adopted to assess the certainty of evidence collected by systematic reviews. The GRADE Evidence-to-Decision framework (EtD) was used to structure the appraisal of evidence and to formulate final recommendations. The EtD and a conflict-of-interests management policy were adopted to minimize the influence of competing interests. Discussion: Full transparency guided the reporting of each step of the process, to support the implementation of recommendations in each context and the future updating process. Considerations for subgroups, monitoring and evaluation of the implementation of recommendations and research priorities were also provided. A two-step review process by external experts and SNLG reviewers, prior to online publication, ensured the methodological robustness underlying final recommendations. Finally, to increase publication timeliness, guidelines are organised in chapters that group sets of related recommendations to be published independently.
Key words:  Cervical cancer      Screening      Recommendations      Evidence-based medicine     
Submitted:  30 March 2021      Revised:  04 May 2021      Accepted:  14 May 2021      Published:  15 August 2021     
*Corresponding Author(s):  Francesco Venturelli     E-mail:  Francesco.venturelli@ausl.re.it
About author:  These authors contributed equally.

Cite this article: 

Francesco Venturelli on behalf of the Multisociety Italian Guidelines for cervical cancer prevention Working Group. Developing evidence-based Multisociety Italian Guidelines for cervical cancer prevention: rationale, methods, and development process. European Journal of Gynaecological Oncology, 2021, 42(4): 634-642.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo4204098     OR     https://ejgo.imrpress.com/EN/Y2021/V42/I4/634

[1] Mario Preti, Niccolò Gallio, Federica Bevilacqua, Giorgia Pasquero, Leonardo Micheletti, Chiara Benedetto. Cervical cone dimension and linear CIN extension trend: 28 years' experience of a tertiary center[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 865-870.
[2] Annarosa Del Mistro, Helena Frayle, Silvia Gori, Alessio Pagan, Marika Soldà, Cesare Romagnolo, Egle Insacco, Licia Laurino, Mario Matteucci, Enrico Busato, Manuel Zorzi, Tiziano Maggino, on behalf of the CIN2 study Working Group. A prospective cohort study to identify biomarkers predicting the regression of grade 2 Cervical Intraepithelial Neoplasia. Study protocol[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 893-898.
[3] Luibov.I. Korolenkova, Ivan.S. Stilidi, Inna.N. Lazareva. Diagnostic value of colposcopy for cervical intraepithelial neoplasia 2–3/carcinoma in situ and microinvasive cervical cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 909-916.
[4] Kelly Baillie, Nicholas Reed, Jennifer Laskey, Jiafeng Pan, Kimberley Kavanagh, Marion Bennie, Christine Crearie, Tanja Mueller, Azmat Sadozye, Rosie Harrand, Ashleigh Kerr, Kathryn Graham. Neoadjuvant chemotherapy in locally advanced cervical cancer: real-world data from the Cancer Medicines Outcomes Programme (CMOP)[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 926-935.
[5] Elif Eda Ozer, Melisa Bagci, Esengul Kocak Uzel, Gulsen Pinar Soydemir, Metin Figen, Meltem Kirli Bolukbas. Comparison of point a based plans with clinical target volume-based three-dimensional plans using dose—volume parameters in small lesion of cervical cancer brachyterapy[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 936-942.
[6] Polo Cornelisz Vermolen, Nienke E. van Trommel, Wouter V. Vogel, Judit A. Adam, Jacobus van der Velden, Constantijne H. Mom. The issue of false positive lymph nodes on [18F] FDG-PET/CT for cervical carcinoma and consequences for treatment[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 943-950.
[7] Jing Fang, Jinmei Fang, Ailin Wu, Yufei Zhao, Yun Liu. Clinical analysis of predisposing factors for radiation enteritis in patients with cervical cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 951-956.
[8] Priscila Thais Silva Mantoani, Daniela Rodrigues Siqueira, Millena Prata Jammal, Eddie Fernando Candido Murta, Rosekeila Simões Nomelini. Immune response in cervical intraepithelial neoplasms[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 973-981.
[9] Francesco Venturelli, Multisociety Italian Guidelines for cervical cancer prevention Working Group. HPV vaccination in women treated for Cervical Intraepithelial Neoplasia grade 2 or 3: evidence-based recommendation from the Multisociety Italian Guidelines for cervical cancer prevention[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 1039-1047.
[10] Gian Marco Prandi, Silvia Cocchio, Marco Fonzo, Patrizia Furlan, Michele Nicoletti, Vincenzo Baldo. Towards the elimination of cervical cancer: HPV epidemiology, real-world experiences and the potential impact of the 9-valent HPV vaccine[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 1068-1078.
[11] Paolo Giorgi Rossi, Anna Iossa, Carmen Beatriz Visioli, Francesco Venturelli, Paola Garutti, on behalf of the GISCi working group on follow up after treatment. Development of evidence-based guidelines for follow up of women treated for cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) in Italian screening programmes[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 1079-1092.
[12] Agnieszka Lewandowska, Lukasz Wicherek, Krzysztof Koper, Sebastian Szubert, Joanna Terlikiewicz, Grzegorz Panek, Marlena Cwynar, Andrzej Roszak, Zaneta Warenczak-Florczak. An analysis of outcomes of patients with locally advanced cervical cancer treated by emergency hysterectomy due to vaginal hemorrhage followed by chemoradiation and surgery in cases of locally advanced cervical cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 682-687.
[13] Maria Szymankiewicz, Sebastian Szubert. Microbiological characteristics of early and late infectious complications following total pelvic exenteration due to cervical cancer recurrence—the significance of infections in long-term outcomes[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 742-751.
[14] Heng Wei, Yang Zhang, Qiao Zhang, Yanming Lu, Yunlong Huo, Ning Wang. Association of the rs2430561 polymorphism of the interferon-𝜸 gene with cervical cancer susceptibility and prognosis in Han Chinese women[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 788-794.
[15] Qihui Feng, Qingli Li, Keyong Bao, Yue Wang, Ping Song, Peng Zuo, Mingzhu Li, Chao Zhao, Na Wang,Jingran Li, Rutie Yin, Lihui Wei. Analysis and comparison of the prevalence and genotype distribution of human papillomavirus in two different areas of China: a cross-sectional study[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 795-801.
No Suggested Reading articles found!